Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$400000.0.

  • Theravance Biopharma's Cash from Financing Activities fell 752.69% to -$400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 9351.88%. This contributed to the annual value of -$2.5 million for FY2024, which is 9874.48% up from last year.
  • Per Theravance Biopharma's latest filing, its Cash from Financing Activities stood at -$400000.0 for Q3 2025, which was down 752.69% from -$503000.0 recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Cash from Financing Activities ranged from a high of $105.3 million in Q2 2021 and a low of -$722.0 million during Q3 2022
  • For the 5-year period, Theravance Biopharma's Cash from Financing Activities averaged around -$45.8 million, with its median value being -$1.4 million (2022).
  • As far as peak fluctuations go, Theravance Biopharma's Cash from Financing Activities surged by 552119.59% in 2021, and later tumbled by 5772857.14% in 2023.
  • Theravance Biopharma's Cash from Financing Activities (Quarter) stood at $149000.0 in 2021, then plummeted by 23906.71% to -$35.5 million in 2022, then increased by 13.71% to -$30.6 million in 2023, then surged by 98.81% to -$365000.0 in 2024, then decreased by 9.59% to -$400000.0 in 2025.
  • Its Cash from Financing Activities stands at -$400000.0 for Q3 2025, versus -$503000.0 for Q2 2025 and -$854000.0 for Q1 2025.